T3	MultiCitation 858 862	[20]
T1	Context 727 869	The MDA-MB-231 cell line used in this study was originally described as Basal B and has been recently characterized as Claudin-low [20], [21].
T2	ACCURATE 25222 25686	These nine cell lines (MDA-MB-435, MDA-MB-436, Hs578T, BT549, MDA-MB-231, MDA-MB-157, SUM1315MO2, SUM159PT and HBL100) showed a gene expression pattern similar to the claudin-low tumor subtype with the lowest expression of genes involved in epithelial cell-cell adhesion (i.e., E-cadherin and claudins 3, 4 and 7), luminal differentiation (i.e., CD24, EpCAM) and high values for the CD44/CD24 and CD49f/EpCAM mRNA ratios (Figure S4, Table S3 in Additional file 1).
T4	ACCURATE 52795 53092	Finally, from a translational point of view, it is interesting to note that the publicly available NCI-60 in vitro drug-screening database includes six breast cancer cell lines, four of which are claudin-low (BT549, MDA-MB-231, MDA-MB-435 and Hs578T) and two of which are luminal (MCF-7 and T47D).
A1	Level T1 Sentence
A2	Level T2 Sentence
A3	Level T4 Sentence
